Related Experiment Video
Updated: May 17, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Expert panel on cost analysis of atrial fibrillation
Ali Serdar Fak1, M Serdar Küçükoğlu, Nazire Afşar Fak
1Practice and Research Center, Marmara University Hypertension and Atherosclerosis Training-İstanbul, Turkey. serdarfak@marmara.edu.tr
Insights
Managing atrial fibrillation (AF) and its complications like heart failure and stroke incurs significant costs. Uncontrolled AF places an extra burden on healthcare economics, impacting treatment expenses.
Area of Science:
- Cardiology
- Health Economics
- Clinical Practice Research
Background:
- Atrial fibrillation (AF) management involves complex comorbidities.
- Cost-effectiveness of AF treatment pathways requires evaluation.
- Guidelines and real-world practice may differ in cost implications.
Purpose of the Study:
- To estimate the total cost of managing atrial fibrillation (AF).
- To compare costs related to acute coronary syndrome, heart failure, stroke, and adverse drug events.
- To analyze costs based on clinical practice versus established guidelines.
Main Methods:
- Cost analysis study utilizing standardized questionnaires.
- Expert-filled forms reflecting daily clinical practice.
- Comparison with ACCF/AHA/ESC guideline recommendations.
Main Results:
- Acute coronary syndrome costs were higher in clinical practice (5,478.43 TL) vs. guidelines (11,319.44 TL).
- Heart failure costs were lower in clinical practice (4,523.74 TL) vs. guidelines (2,925.86 TL).
- Stroke costs varied, with clinical practice at 5,719.25 TL and guidelines at 7,931.18 TL.
Conclusions:
- Clinical practice and guideline-based management of AF and its complications present differing economic burdens.
- Uncontrolled AF significantly impacts health economics.
- Further research into cost-effective AF management strategies is warranted.
Objective:
To estimate total cost of atrial fibrillation (AF) management concerning acute coronary syndrome, heart failure, stroke and drug related adverse events with respect to clinical practice and available guidelines.
Methods:
This cost analysis study was based on identification of total costs related to management of acute coronary syndrome, heart failure, stroke and the drug related adverse events in patients with AF based on standardized questionnaire forms filled by experts according to their daily clinical practice and also to ACCF/AHA/ESC guidelines. Total cost included cost items related to treatment, healthcare resources utilization, and diagnostic test and consultations.
Results:
The yearly cost of acute coronary syndrome per patient was 5.478.43 TL according to expert's view reflecting real clinical practice whereas it was 11.319.44 TL when calculation was based on recommendations in the guidelines. The average total cost of heart failure was 4.523.74 TL according to expert's view whereas it was 2.925.86 TL based on guidelines. The average total cost of stroke was 5.719.25 TL according to expert's view but 7.931.18 TL based on guidelines. Among drug related adverse events, only those related to cardiac adverse events were estimated to be higher according to expert view as compared to guideline recommendations (288.65 vs. 150.99 TL).
Conclusions:
Reflecting the treatment algorithms in the management of AF and related adverse events, our findings seem to emphasize the extra burden on health economics posed by patients suffering from the uncontrolled disease.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Acute Coronary Syndrome III: Diagnostic Studies
Rheumatic Heart Disease III: Medical Management
Dysrhythmias V: Evaluating Dysrhythmias

